The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Verditek falls on cash shell plans

Wed, 07th Feb 2024 09:29

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Redx Pharma PLC, up 35% at 27.00 pence, 12-month range 19.00p-60.00p. The clinical-stage biotechnology company signs an agreement to sell Kirsten rat sarcoma virus inhibitor program to Jazz Pharmaceuticals PLC. Redx says it will receive USD10 million upfront, with a potential for up to USD870 million in development, regulatory and sales milestone payments in addition to royalties on future net sales. Jazz and Redx will collaborate to advance candidates through IND-enabling studies; Jazz will be responsible for all clinical development, regulatory, manufacturing and commercialization activities.

----------

AIM - LOSERS

----------

Verditek PLC, down 19% at 0.12p, 12-month range 0.080p-1.90p. The producer of lightweight solar panels agrees terms to sell its solar business to a new company, which will be established by the holders of Verditek's secured convertible loan notes for GBP528,340 in notes and GBP50,000 in cash. Upon disposal, Verditek will be regarded as an AIM rule 15 cash shell. Verditek will therefore need to, within six months, make an acquisition or acquisitions which constitute a reverse takeover. It said that it is currently in discussions with "a group of individuals", who it is proposed would come in as a new management team with a view to completing a fundraise of about GBP300,000. The aim would be to conduct a reverse takeover within 6 months of completion of the disposal. "There is no guarantee that this proposal will proceed as it still at an exploratory stage and the company will update the market with more information as soon as it is available," Veritek adds.

----------

Helium One Global Ltd, down 16% at 1.81p, 12-month range 0.19p-10.30p. The primary helium explorer raises GBP4.7 million through a placing of 313.3 million new shares priced at 1.5p each. The placing price represents a 30% discount to the closing price of 2.16p on Tuesday. The proceeds will provide the company with "sufficient" working capital to progress its planning for the next stage of the work programme in Tanzania. Chief Executive Lorna Blaisse says: "The results that we have achieved from the Itumbula West-1 well, flowing helium to surface in such significant concentrations, has confirmed a globally unique helium producing province. By moving quickly and finalising this company led placing early on, we have been able to strengthen our working capital position, which will enable us to fully focus on the next phase of the company's growth."

----------

By Sophie Rose, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
10 Jul 2019 10:40

WINNERS & LOSERS SUMMARY: PageGroup Slumps After Profit Warning

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - LOSERS----------Micro Focus down

Read more
10 Jul 2019 09:41

Redx Pharma Shares Double After Jazz Pharmaceutical Deal

(Alliance News) - Redx Pharma PLC said Wednesday it has signed a definitive agreement with Nasdaq-listed Jazz Pharmaceuticals PLC to sell its pan-RAF inhibitor programme.Shares in the and a

Read more
10 Jun 2019 10:10

Redx Pharma Gets GBP2.5 Million Financing As Interim Loss Narrows

LONDON (Alliance News) - Redx Pharma PLC on Monday said its loss narrowed in the first half of its current financial year as it progresses on cancer and idiopathic pulmonary fibrosis drugs the and

Read more
10 Jun 2019 08:29

Redx Pharma narrows losses as RXC004 trials recommence

(Sharecast News) - Drug discovery and development company Redx Pharma published its interim results on Monday, revealing it had narrowed first-half losses as it progresses on cancer and idiopathic pulmonary fibrosis drugs development.

Read more
3 May 2019 14:07

Redx Pharma Exploring New Financing Options Despite Progress

LONDON (Alliance News) - Cancer and fibrosis-focused drug firm Redx Pharma PLC is "greatly encouraged" by talks over securing new financing.In November, Redx said it was looking a

Read more
3 May 2019 11:17

Redx Pharma extends cash runway into July

(Sharecast News) - Drug discovery and development company Redx Pharma updated the market on its ongoing plans to strengthen its balance sheet on Friday, with its board reiterating its commitment to strengthening the balance sheet in order to extend the cash runway beyond the second quarter of 2019, as it initially announced in November.

Read more
12 Feb 2019 13:42

Redx Pharma reveals promising data on 'ROCK2' compound

(Sharecast News) - Drug discovery and development company Redx Pharma announced promising preclinical efficacy data for its lead selective 'ROCK2' compound on Tuesday.

Read more
12 Feb 2019 09:45

Redx Pharma Sees Promising Results From Liver Disease Treatment

LONDON (Alliance News) - Redx Pharma PLC said Tuesday that preclinical efficacy data for its ROCK2 compound showed the product was able to have an impact on established fibrosis.Shares in a

Read more
6 Feb 2019 11:45

Redx Pharma Receives Oustanding Loan Amounts From Redag

LONDON (Alliance News) - Redx Pharma PLC on Wednesday said that it received a full cash repayment of GBP869,126, representing the outstanding amount of a loan made in 2014 to Redag Crop Protection

Read more
31 Jan 2019 11:03

Deinove Backs Out Of Anti-Infective NBTI Programme With Redx Pharma

LONDON (Alliance News) - Redx Pharma PLC on Thursday said French biotech firm Deinove SA will not exercise its option for Redx's novel bacterial topoisomerase inhibitor programme.Shares

Read more
31 Jan 2019 09:45

Deinove hands rights to NBTI programme back to Redx Pharma

(Sharecast News) - Drug discovery and development company Redx Pharma announced on Thursday that Deinove had decided not to exercise its option for Redx's 'Novel Bacterial Topoisomerase Inhibitor' (NBTI) programme.

Read more
30 Nov 2018 10:36

Redx Pharma Drug Candidate RXC006 To Be Developed As Fibrosis Drug

LONDON (Alliance News) - Drug developer Redx Pharma PLC said Friday its RXC006 drug candidate was able to suppress lung fibrosis in living organisms and will be developed as a treatment for in up

Read more
30 Nov 2018 10:31

Redx Pharma jumps as first data shows 'great potential' for fibrosis candidate

(Sharecast News) - Redx Pharma made gains on Friday after it said that pre-clinical data suggested that its RXC006 drug candidate has "great potential" as a treatment for fibrosis.

Read more
19 Nov 2018 13:07

Redx Pharma Posts Large Annual Loss, Appoints Astra Executive As CFO

LONDON (Alliance News) - Redx Pharma PLC on Monday posted a large loss due to the absence of a big exceptional disposal gain seen a year before and said that it has appointed James Mead as its new

Read more
19 Nov 2018 08:59

Redx Pharma swings to a loss following 'seminal' year

(Sharecast News) - A year after clambering out of administration, drug discovery and development outfit Redx Pharma swung to a loss but remains confident of making progress with a drug pipeline refocused on cancer and fibrosis.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.